Zenagamtide weekly injections for weight loss in Asian adults with overweight or obesity
Tests zenagamtide against placebo in Asian adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
Key facts
- Where
- Cheras, Lembah Pantai, Malacca, Miri, and Putrajaya, MalaysiaSee the 5 sites
- Phase
- Phase 3
Where in Malaysia
- Hospital Canselor Tuanku Muhriz UKMCheras, MalaysiaNo longer taking part
- University Malaya Medical CentreLembah Pantai, MalaysiaNo longer taking part
- Hospital MelakaMalacca, MalaysiaNo longer taking part
- Hospital MiriMiri, MalaysiaNo longer taking part
- Hospital PutrajayaPutrajaya, MalaysiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07668401
- Record updated
- 24 August 2026
- Original description
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.Read full original descriptionShow less
Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or above at the time of signing the informed consent.
Exclusion: Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening; History of type 1 or type 2 diabetes mellitus; Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening.